AWG News

Home / AWG News

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2017

WASHINGTON, Oct. 3, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at IDWeek 2017 taking place in San Diego from October 4 – 8. In addition to 59 poster presentations, representatives from AWG member companies will be participating in various panels and symposiums addressing the current state of the antimicrobial development pipeline. IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases. “AWG is proud to share data from our member companies...

Read More

Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program

WASHINGTON, Sept. 6, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) is pleased to announce that two of its member companies, T2 Biosystems, Inc. (NASDAQ: TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, and Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, have entered into an exclusive partnership for commercial placement of T2Dx Instruments to support CD101 drug trials. The program is designed to accelerate enrollment in Cidara’s CD101 trials targeting the deadly sepsis-causing pathogen Candida, and to increase uptake of T2’s products. “The AWG is excited to highlight this collaboration...

Read More

Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel

WASHINGTON, June 19, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today that Jeffrey Stein, Ph.D., Chairman of AWG and President and Chief Executive Officer of Cidara Therapeutics, Inc. (Nasdaq: CDTX), Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, Inc. (Nasdaq: SCYX), and Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet Pharmaceuticals, Inc. will be participating in an interactive panel discussion at the 2017 BIO International Convention, taking place June 19-22 in San Diego, CA. The panel titled, “Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals” will focus on the growing global public health epidemic caused by fungal infections and highlight...

Read More

Antimicrobials Working Group Announces New Leadership Team

WASHINGTON, Jan. 11, 2017 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the election of a new Chairman, Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, Inc. (NASDAQ: CDTX), as well as Vice Chairs Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) and Eugene Sun, M.D., CEO of Melinta Therapeutics. Dr. Prabhavathi Fernandes has stepped down from her role as Chair of AWG after three years of service. “On behalf of the AWG I would like to thank Dr. Fernandes for her service to the AWG membership since 2013. Under her leadership the coalition has grown substantially...

Read More

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018

WASHINGTON, Oct. 3, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical and research programs at IDWeek 2018 to be held October 3-7 in San Francisco. AWG members are presenting a total of 40 poster presentations, four oral abstract presentations and four features within the symposium entitled “Exploring the Antibiotic Pipeline 2018.” IDWeek is an annual scientific meeting that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology...

Read More

Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

WASHINGTON, Jan. 29, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (Nasdaq: SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Additionally, AWG recently welcomed Vical Incorporated (Nasdaq: VICL), a biopharmaceutical company focused on the development of...

Read More

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

  WASHINGTON, Jan. 29, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (Nasdaq: SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Additionally, AWG recently welcomed Vical Incorporated (Nasdaq: VICL), a biopharmaceutical company focused on the development...

Read More

Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

WASHINGTON, Jan. 29, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (Nasdaq: SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Additionally, AWG recently welcomed Vical Incorporated (Nasdaq: VICL), a biopharmaceutical company focused on the development of...

Read More

X-Biotix Licenses Harvard Technology, Establishes Research Collaboration To Combat Antibiotic Resistance

X-Biotix Licenses Harvard Technology, Establishes Research Collaboration To Combat Antibiotic Resistance Launches out of X-Chem and Leverages DNA-Encoding Library Technology WALTHAM, Mass. May 30, 2017 – X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multi-drugresistant (MDR) Gram-negative pathogens, announced today that it has initiated a joint research effort with key collaborators at Harvard Medical School (HMS) to address the urgent and growing threat of antibiotic resistance. Through a collaboration and license agreement with Harvard’s Office of Technology Development, X-Biotix will access the expertise of Thomas Bernhardt, Ph.D., Stephen...

Read More